GLP-1 medications have become one of the biggest stories in weight loss. Drugs such as semaglutide, sold as Wegovy and Ozempic,…October 06, 2026
They are powerful medications. But powerful appetite suppression should not be confused with learning how to live at a healthy weight.
My concern with any weight-loss approach is what happens when the treatment bypasses the very habits that a person ultimately needs for long-term health.
A person still needs to learn how to:
- Eat appropriately for his or her individual physiology, metabolism, genetics, food tolerances, activity level, and health history.
- Choose nutrient-dense foods rather than simply eating less food.
- Exercise regularly, including resistance exercise to preserve muscle.
- Develop a healthy psychological relationship with food.
- Recognize emotional and stress-related eating.
- Address chronic psychological and physiologic stress.
- Establish eating habits that can be maintained for life rather than chasing a short-term number on a scale.
Weight loss and health are not identical.
A person can weigh less and still be nutritionally depleted, physically weak, metabolically unhealthy, or dependent on medication to maintain the behavioral pattern that produced the weight reduction.
Appetite Suppression Creates a Nutritional Problem That Deserves More Attention
One of the principal reasons GLP-1 drugs work is that people become much less hungry and consequently eat considerably less.
That sounds desirable when excess calories are the problem. But the body does not need only calories. It requires adequate protein, essential fatty acids, vitamins, minerals, fiber, and other nutrients every day.
Recent nutritional literature has begun paying much more attention to this issue.
A 2025 review reported that GLP-1 therapy can reduce food intake substantially and warned that reduced intake can increase the risk of micronutrient inadequacy and muscle loss, particularly when patients are not receiving nutritional counseling. https://pubmed.ncbi.nlm.nih.gov/41328178/
A 2026 review examining nearly half a million patients found signals involving vitamin D, iron, calcium, thiamine, vitamin B12 and protein adequacy. The authors emphasized that much of the current evidence is observational, so GLP-1 drugs cannot yet be blamed as the direct cause of every deficiency; however, the nutritional concern is real. https://pubmed.ncbi.nlm.nih.gov/41549912/
Other recent reviews have identified potential inadequacies involving protein, vitamin D, thiamine and other B vitamins, iron, calcium, magnesium, potassium, zinc and folate, especially in patients whose appetite becomes severely reduced or who have persistent nausea and vomiting. https://pubmed.ncbi.nlm.nih.gov/41373949/
The mechanism is not difficult to understand.
If someone previously had a poor diet and then a medication causes that person to eat only half as much food, he may simply be eating half as much of an already inadequate diet.
That is not nutritional rehabilitation.
Muscle Loss Is Another Concern
Weight loss includes more than fat loss.
Some lean tissue is normally lost during substantial weight reduction, and GLP-1-associated weight loss is no exception. Clinical reviews have therefore emphasized adequate protein intake and resistance exercise to help preserve muscle and physical function. https://pubmed.ncbi.nlm.nih.gov/42036071/
This becomes particularly important in older patients.
A person can celebrate losing 40 pounds while failing to ask:
How much was fat, and how much was muscle?
Maintaining strength, mobility, metabolic health and functional independence is far more important than simply obtaining a lower scale reading.
Recognized Side Effects and Safety Concerns of GLP-1-Based Drugs
The adverse-effect profile varies somewhat among individual drugs, and tirzepatide is technically a dual GIP/GLP-1 receptor agonist rather than a pure GLP-1 drug. Nevertheless, the major recognized and reported concerns include the following.
Common gastrointestinal effects include nausea, vomiting, diarrhea, constipation, abdominal pain, abdominal distention, indigestion, belching, reflux, reduced appetite and early fullness.
Severe gastrointestinal problems can include persistent vomiting, severe constipation and clinically significant slowing of gastric emptying. These drugs are generally approached cautiously in patients with severe gastroparesis. FDA labeling for tirzepatide specifically warns about sometimes-severe gastrointestinal adverse reactions. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s037lbl.pdf?utm_source=chatgpt.com
Dehydration and kidney injury can occur when nausea, vomiting or diarrhea causes substantial fluid loss. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s037lbl.pdf?utm_source=chatgpt.com
Gallstones and gallbladder inflammation have occurred, particularly in association with substantial or rapid weight loss. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s037lbl.pdf?utm_source=chatgpt.com
Pancreatitis is an uncommon but potentially serious adverse event included in prescribing warnings. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s037lbl.pdf?utm_source=chatgpt.com
Hypoglycemia can occur, particularly when these medications are combined with insulin or drugs such as sulfonylureas. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s037lbl.pdf?utm_source=chatgpt.com
Diabetic retinopathy can temporarily worsen, particularly when blood glucose improves rapidly in a patient who already has diabetic retinal disease.
Possible optic-nerve injury and vision loss—NAION—is an emerging concern with semaglutide. Several large observational studies have reported an association between semaglutide and non-arteritic anterior ischemic optic neuropathy, which can produce sudden, painless and sometimes permanent vision loss. However, studies have not been entirely consistent, and the absolute risk appears small. A 2026 meta-analysis characterized the certainty of the evidence as low, while another recent analysis found an elevated relative risk but a very small absolute risk. https://pubmed.ncbi.nlm.nih.gov/41692115/
The concern is sufficiently serious that some regulators have updated semaglutide safety information and recommend urgent ophthalmologic evaluation for sudden visual symptoms. Saudi Food and Drug Authority
Pulmonary aspiration during anesthesia or deep sedation has been reported because delayed gastric emptying can leave food in the stomach despite customary fasting. FDA labeling now includes this warning. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s037lbl.pdf?utm_source=chatgpt.com
Hair loss has been reported, especially during substantial weight reduction.
Fatigue, dizziness and headache may occur.
Injection-site reactions may occur.
Allergic and hypersensitivity reactions, including rare anaphylaxis and angioedema, have been reported. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s037lbl.pdf?utm_source=chatgpt.com
A modest increase in heart rate has been observed with some agents.
Medication absorption can be altered because gastric emptying is delayed. Tirzepatide labeling specifically warns that absorption of oral medications can be affected. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s037lbl.pdf?utm_source=chatgpt.com
For women taking tirzepatide, delayed gastric emptying can reduce the effectiveness of oral hormonal contraceptives, particularly after starting therapy or increasing the dosage. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s037lbl.pdf?utm_source=chatgpt.com
Thyroid C-cell tumors are a boxed-warning issue for several of these medications. Animal studies found thyroid C-cell tumors, although whether the same risk exists in humans remains uncertain. These drugs are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN type 2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s037lbl.pdf?utm_source=chatgpt.com
Nutritional inadequacy and deficiency may develop when appetite suppression results in insufficient intake of protein, vitamins and minerals. Emerging evidence particularly points toward concerns involving vitamin D, iron, calcium, magnesium, potassium, zinc, thiamine, vitamin B12 and folate. https://pubmed.ncbi.nlm.nih.gov/41549912/
Loss of lean muscle mass and possibly bone mass can accompany substantial weight loss, particularly when protein intake and resistance exercise are inadequate. PubMed
It is important to distinguish these established and emerging risks from claims that have not held up. For example, FDA's later review did not support an increased risk of suicidal thoughts or behavior from GLP-1 medications. https://www.fda.gov/drugs/drug-safety-communications/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type?blog_category=Medications+%26+treatments%2CWeight+management&blog_tag=Mounjaro%2Cno-excerpt%2Csemaglutide%2CWegovy%2CZepbound&utm_source=chatgpt.com
What Happens When the Drug Is Stopped?
This is perhaps one of the most important questions.
If a person loses weight because a medication suppresses hunger but never changes food selection, stress responses, eating behavior, exercise habits or lifestyle, what happens when the medication is discontinued?
Appetite frequently returns.
Without a new lifestyle already in place, weight regain should not be surprising.
That does not mean the medication has failed pharmacologically. It means obesity and weight regulation are chronic biological and behavioral problems, and simply suppressing one biological signal does not automatically teach a person how to eat and live.
Medication Should Not Become a Substitute for Health
There are people for whom GLP-1 drugs may be medically appropriate. These drugs have demonstrated meaningful benefits in selected patients with obesity, diabetes and cardiovascular disease. They should therefore not be dismissed as pharmacologically ineffective “gimmicks.”
The problem arises when the medication becomes a substitute for the fundamentals of health.
A sound weight-management program should still ask:
What is this person eating?
Are they getting enough protein?
Are they getting adequate vitamins and minerals?
Are they exercising and preserving muscle?
What drives their eating behavior?
Are stress, depression, loneliness, fatigue or habit contributing to overeating?
Can this eating pattern be maintained for the rest of the person's life?
And perhaps most importantly:
Are we improving health, or merely lowering weight?
The Goal Should Be a Lifestyle, Not a Temporary Weight-Loss Project
Proper weight control is not a 12-week project.
Eating correctly should eventually become as normal as brushing your teeth. Exercise should become part of life. Healthy food should cease being regarded as temporary punishment undertaken until a target weight is reached.
Patients need to develop a relationship with food in which food nourishes the body rather than continually serving as entertainment, reward, sedation or stress relief.
For some people, medication may be one tool within that process.
But it should never replace the process.
The most durable goal remains the same: teach the body and the person to live healthfully—not merely teach the scale to display a smaller number.
Keefe Clinic Fullscript dispensary link is:
https://us.fullscript.com/welcome/jkeefe-dc
Keefe Clinic
John H. Keefe III, D.C., P.C.
5640 South Memorial Drive, Suite A
Tulsa, Oklahoma 74145-9001
At 57th & Memorial
Phone: (918) 663-1111
Fax: (918) 663-2129
Email: docjohn@keefeclinic.com
Website: KeefeClinic.comEdit